GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » EV-to-FCF

Oramed Pharmaceuticals (XTAE:ORMP) EV-to-FCF : 1.32 (As of May. 12, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Oramed Pharmaceuticals's Enterprise Value is ₪-51.77 Mil. Oramed Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-39.34 Mil. Therefore, Oramed Pharmaceuticals's EV-to-FCF for today is 1.32.

The historical rank and industry rank for Oramed Pharmaceuticals's EV-to-FCF or its related term are showing as below:

XTAE:ORMP' s EV-to-FCF Range Over the Past 10 Years
Min: -49.31   Med: -2.96   Max: 29.05
Current: 1.27

During the past 13 years, the highest EV-to-FCF of Oramed Pharmaceuticals was 29.05. The lowest was -49.31. And the median was -2.96.

XTAE:ORMP's EV-to-FCF is ranked better than
60.26% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs XTAE:ORMP: 1.27

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Oramed Pharmaceuticals's stock price is ₪8.837. Oramed Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.522. Therefore, Oramed Pharmaceuticals's PE Ratio for today is 16.93.


Oramed Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Oramed Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals EV-to-FCF Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.96 -3.42 -27.91 -11.28 1.72

Oramed Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.28 2.67 0.33 -0.30 1.72

Competitive Comparison of Oramed Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Oramed Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's EV-to-FCF falls into.



Oramed Pharmaceuticals EV-to-FCF Calculation

Oramed Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-51.771/-39.337
=1.32

Oramed Pharmaceuticals's current Enterprise Value is ₪-51.77 Mil.
Oramed Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-39.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oramed Pharmaceuticals  (XTAE:ORMP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Oramed Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.837/0.522
=16.93

Oramed Pharmaceuticals's share price for today is ₪8.837.
Oramed Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.522.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Oramed Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals (XTAE:ORMP) Business Description

Comparable Companies
Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.